Fortrea Holdings Inc. Overview
Pro stress-test →Fortrea is a global contract research organization (CRO) and provider of clinical development solutions to the life sciences industry. The company delivers comprehensive Phase I through IV study management, clinical pharmacology, and market access solutions to biopharma and MedTech companies around the world. As a newly independent public company spun off from Labcorp in July 2023, Fortrea addresses the entire clinical trial lifecycle for pharmaceutical and medical device developers.
Strategic Profile
Pro stress-test →With more than three decades of experience and insights, and a laser focus on customer needs, Fortrea has the breadth and depth to meet global needs, and the nimbleness to innovate at the speed of change. The company's talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. The company strategically focuses on oncology, central nervous system, rare diseases, and cell and gene therapies.
Competitive Landscape
Pro stress-test →Fortrea competes in the global CRO market against established players including IQVIA, Charles River Laboratories (CRL), Parexel (now part of EPS), Syneos Health, and smaller specialized CROs. The market is characterized by consolidation, with Fortrea's recent independence and focus on Phase I-IV capabilities positioning it as a mid-sized player with differentiation in oncology and cell/gene therapy expertise. The company's scale and geographic presence across 90+ countries provide competitive advantages against smaller regional players.
Industry Context
Fortrea Holdings Inc. operates in Contract Research Organizations / Clinical Trial Management / Life Sciences Professional Services.
Key facts
Founded: 1968 · Headquarters: Durham, North Carolina, United States · Employees: 19,000